Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Gaffney C, Golan R, Cantu MD, Scognamiglio T, McCarthy H, Mosquera JM, et al. The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer. J Urol. 2019;202(1):96-101.

Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.

Hwang JH, Seo J-, Beshiri ML, Wankowicz S, Liu D, Cheung A, et al. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019;29(8):2355-2370.e6.

Solomon JP, Hechtman JF. Detection of Fusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Res. 2019;79(13):3163-3168.

Shen Z-, Postnikoff S, Tyler JK. Is Gcn4-induced autophagy the ultimate downstream mechanism by which hormesis extends yeast replicative lifespan? Curr Genet. 2019;65(3):717-720.

Schatz-Siemers N, Brandler TC, Oweity T, Sun W, Hernandez A, Levine P. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation. Diagn Cytopathol. 2019;47(10):977-985.

Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, et al. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors. Clin Cancer Res. 2019;25(2):573-583.

DeSimone RA, Hayden JA, Mazur CA, Vasovic LV, Sachais BS, Zhao Z, et al. Red blood cells donated by smokers: A pilot investigation of recipient transfusion outcomes. Transfusion. 2019;59(8):2537-2543.

Toyoda Y, Franck P, Brownstone ND, Lieberman M, Magro CM, Otterburn DM. Apocrine adenocarcinoma in the setting of apocrine hidrocystoma of the leg. Dermatol Online J. 2019;25(6).

Mancuso CJ, Magro CM, Lipner SR. Acquired digital fibrokeratoma presenting as a painless nodule on the right fifth fingernail. Cutis. 2019;103(6):340-342.